Edwards Lifesciences Corporation (EW): Price and Financial Metrics


Edwards Lifesciences Corporation (EW): $89.49

1.55 (+1.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EW POWR Grades


  • Quality is the dimension where EW ranks best; there it ranks ahead of 92.62% of US stocks.
  • The strongest trend for EW is in Stability, which has been heading up over the past 206 days.
  • EW ranks lowest in Momentum; there it ranks in the 16th percentile.

EW Stock Summary

  • EW has a market capitalization of $54,666,738,169 -- more than approximately 95.61% of US stocks.
  • Price to trailing twelve month operating cash flow for EW is currently 47.63, higher than 91.17% of US stocks with positive operating cash flow.
  • In terms of volatility of its share price, EW is more volatile than just 4.12% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Edwards Lifesciences Corp, a group of peers worth examining would be EMR, PHG, NEM, ETN, and HUM.
  • EW's SEC filings can be seen here. And to visit Edwards Lifesciences Corp's official web site, go to www.edwards.com.

EW Price Target

For more insight on analysts targets of EW, see our EW price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $98.35 Average Broker Recommendation 1.62 (Moderate Buy)

EW Stock Price Chart Interactive Chart >

Price chart for EW

EW Price/Volume Stats

Current price $89.49 52-week high $98.11
Prev. close $87.94 52-week low $66.23
Day low $88.01 Volume 2,074,700
Day high $89.94 Avg. volume 2,692,742
50-day MA $86.91 Dividend yield N/A
200-day MA $84.02 Market Cap 55.63B

Edwards Lifesciences Corporation (EW) Company Bio


Edwards Lifesciences provides products and technologies to treat structural heart disease and critically ill patients worldwide. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company was founded in 1999 and is based in Irvine, California.

EW Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$89.49$17.4 -81%

Below please find a table outlining a discounted cash flow forecast for EW, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Edwards Lifesciences Corp ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Edwards Lifesciences Corp ended up being:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 99. Notably, its equity weight is greater than 90.21% of US equities in the Healthcare sector yielding a positive free cash flow.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 8.23% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • EW's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 52.18% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-81%
1%-81%
2%-81%
3%-81%
4%-81%
5%-80%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as EW, try MDT, SRDX, MTD, NUVA, and XRAY.


EW Latest News Stream


Event/Time News Detail
Loading, please wait...

EW Latest Social Stream


Loading social stream, please wait...

View Full EW Social Stream

Latest EW News From Around the Web

Below are the latest news stories about Edwards Lifesciences Corp that investors may wish to consider to help them evaluate EW as an investment opportunity.

Top 1st-Quarter Trades of Frank Sands' Firm

Sands Capital Management ups stakes in tech picks, trims Adobe

Yahoo | May 14, 2021

Is Edwards Lifesciences (NYSE:EW) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | May 12, 2021

Top Research Reports for JPMorgan, Home Depot & Merck

Top Research Reports for JPMorgan, Home Depot & Merck

Yahoo | May 7, 2021

Leerink Partners Stick to Their Buy Rating for Edwards Lifesciences By Investing.com

Leerink Partners Stick to Their Buy Rating for Edwards Lifesciences

Investing.com | April 22, 2021

Edwards Lifesciences (EW) Surges 6.3%: Is This an Indication of Further Gains?

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | April 22, 2021

Read More 'EW' Stories Here

EW Price Returns

1-mo 0.53%
3-mo 2.89%
6-mo 4.99%
1-year 26.07%
3-year 97.48%
5-year 169.03%
YTD -1.91%
2020 17.32%
2019 52.31%
2018 35.90%
2017 20.29%
2016 18.64%

Continue Researching EW

Here are a few links from around the web to help you further your research on Edwards Lifesciences Corp's stock as an investment opportunity:

Edwards Lifesciences Corp (EW) Stock Price | Nasdaq
Edwards Lifesciences Corp (EW) Stock Quote, History and News - Yahoo Finance
Edwards Lifesciences Corp (EW) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8414 seconds.